Ocaliva/obeticholic acid Cost, Side effects, Dosage, Uses in primary biliary cholangitis

Ocaliva/obeticholic acid Cost, Side effects, Dosage, Uses in primary biliary cholangitis. Ocaliva is manufactured by New York, New York-based Intercept Pharmaceuticals, Inc.

Food and Drug Administration has approved Ocaliva that contains active ingredient obeticholic acid for the treatment of primary biliary cholangitis (PBC). FDA proposed this drug  to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to ursodeoxycholic acid, or as a single therapy in adults unable to tolerate UDCA.

Ocaliva, given orally, ties to the farnesoid X receptor (FXR), a receptor found in the core of cells in the liver and digestive system. FXR is a key controller of hepatic metabolic pathways. Ocaliva expands bile stream from the liver and stifles bile acid creation in the liver, in this way decreasing the exposure of the liver to lethal levels of biliary contents.

PBC is an chronic, or long lasting, illness that causes blockage of biliary system in the liver to end up kindled, harmed and at last pulverized. This causes bile to stay in the liver, which harms the liver cells after some time, and results in cirrhosis, or scarring of the liver. As cirrhosis advances, and the measure of scar tissue in the liver expands, the liver loses its capacity to work.
Ocaliva/obeticholic acid Cost, Side effects, Dosage, Uses in primary biliary cholangitis
Ocaliva/obeticholic acid Cost, Side effects, Dosage, Uses in primary biliary cholangitis

Ocaliva Side effects

The most common side effects of Ocaliva are

  • Pain in the middle part of the throat (oropharyngeal)
  • Severe itching of the skin (pruritus)
  • Abdominal pain and discomfort
  • Generalized weakness
  • Joint pain (arthralgia)
  • Fatigue
  • Dizziness
  • Constipation
  • Headache
  • Mild fever

Ocaliva should not be used in patients with complete biliary obstruction.

Ocaliva Uses or Prescribing information 

Patients left untreated, or who have not reacted to ursodeoxycholic acid, are at danger for liver cirrhosis and death. Ocaliva gives a vital treatment choice to patients living with initial biliary cholangitis who have not responded to the main other affirmed treatment, ursodeoxycholic acid.

Ocaliva is reserved for the treatment of initial biliary cholangitis in combination with ursodeoxycholic acid in grown-ups with a deficient response to ursodeoxycholic acid, or as a solitary treatment in grown-ups not able to endure ursodeoxycholic acid.

Ocaliva Cost/Price

According to market survey average cost of 30 ocaliva tablets with potency of 5mg is approximately 5840$ to 5890$. Similarly 30 ocaliva talets with potency of 10mg is approximately 6000$ to 6250$. This cost or price may vary due to number of factors like location, discount policy or coupon system. Ocaliva is now available in two pack size 30's and 90's. This price may variate with the passage of time so, make it confirm by visiting your nearby pharmacy before purchasing.

Ocaliva Dosage

Ocaliva is available in two potencies 5mg and 10mg. Usual dose of ocaliva at startup is 5mg orally every day. If it does not give adequate response after taking 2-3 weeks then dose may titerate up-to 10mg once a day. Dose should not be exceed 10mg/day.

Zinbryta/daclizumab Cost, Side effects, Uses, Dosage for multiple sclerosis

Zinbryta/daclizumab Cost, Side effects, Uses, Dosage for multiple sclerosis. Zinbryta is manufactured by Biogen, Inc. of Cambridge, Massachusetts.

The U.S. Food and Drug Administration has been approved Zinbryta that contains active ingredient daclizumab for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta belongs to a class termed as monoclonal antibodies. Zinbryta is presented in parentral dosage form and categorized as long acting agent.

Zinbryta should be reserved for  those patients who have had a deficient response to combination therapy for multiple sclerosis (MS) on the grounds that Zinbryta has genuine dangers including liver damaging effects and modulation of immune system. In light of the dangers, Zinbryta has a boxed cautioning and is accessible just through a limited circulation program under a risk Evaluation and mitigation Strategy.

MS is a chronic, provocative, immune system malady of the focal sensory system that disturbs the co-ordination between the spinal region and different parts of the body. It is among the most widely recognized reasons for neurological disability in adults and happens more often in ladies than men. For the vast majority with MS, episodes of worsening function (relapses) are initially followed by recovery periods (remissions).


Zinbryta Side effects

The most common adverse reactions that wrere observed during Zinbryta therapy are
  • Cold symptoms (nasopharyngitis)
  •  Increased alanine aminotransferase
  • Throat (oropharyngeal) pain
  • Enlargement of lymph nodes
  • Upper respiratory tract infection
  • Rash
  • Influenza
  • Dermatitis
  • Eczema
  • Depression

 Zinbryta Uses or prescribing information

Due to serious side effects produced by Zinbryta it should be reserved for those patients who have had a deficient response to combination therapy for multiple sclerosis (MS) or relapsing forms of multiple sclerosis (MS)

The viability of Zinbryta was appeared in two clinical trials. One trial conducted at Zinbryta and Avonex in 1,841 members who were studied for 144 weeks. Patients on Zinbryta had less relapses than patients taking Avonex.

The second trial was conducted between Zinbryta and inactive agent (placebo) and included 412 members who were dealt with for 52 weeks. In that study, those accepting Zinbryta had less relapses as compared with those getting inactive agent.

Zinbryta Cost/Price

This drug is now available in market in a single-dose prefilled syringe with potency of 150mg/ml. According to market survey initial price of a single-dose prefilled syringe of zinbryta costs about 7000$ - 7600$. This price may variate with the passage of time so, make it confirm by visiting your nearby pharmacy before purchasing.

Zinbryta Dosage

In adults, usual dosage frequency of zinbryta is 150mg subcutaneously (SC) once in a month in case of recurrent episodes of multiple sclerosis. Dose titration may be required in case of liver impairment. In children, safety profile of zinbryta/daclizumab has not yet evaluated.

Tecentriq/atezolizumab Cost, Side effects, dosage, Uses for bladder cancer

Tecentriq/atezolizumab Cost, Side effects, dosage, Uses for bladder cancer. Tecentriq is marketed by Genentech based in San Francisco, California. The Ventana PD-L1 (SP142) assay complementary diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.

Tecentriq acts on the PD-1/PD-L1 pathway (proteins found on the body's immune cells and some tumor cells). By blocking these co-ordinations, Tecentriq may help the body's defense system to cope with tumor cells. Tecentriq is the first FDA-affirmed PD-L1 inhibitor and the most recent in the broader class of PD-1/PD-L1 agent endorsed by the FDA in previous two years.

Tecentriq is reserved for the treatment of patients with locally progressed or metastatic urothelial carcinoma whose disease has became more severe after continuous administration of platinum-containing chemotherapy, or within range of 12 months of getting platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment. Urothelial carcinoma has high prevalence rate as compared to other type of bladder cancer. It takes place in the urinary system and spreads rapid to surrounding organs.




Tecentriq/atezolizumab Side effects

The safety and efficacy of Tecentriq were studied in a single-arm clinical trial involving 310 patients with locally advanced or metastatic urothelial carcinoma. Most common side effects that were observed during therapy are 
  • Urinary tract infection,
  • Decreased appetite, 
  • Nausea, 
  • Constipation
  • Fatigue,
  • Fever (pyrexia) 
  • Increased risk of infection 
  • Changes in immune system response
  • Rashes
  • Hypersensitivity

Tecentriq/atezolizumab Uses or Indications

FDA approved tecentriq/atezolizumab for the treatment of progressive or advance urothelial carcinoma. This drug is also indicated for those who have became more severe after continuous administration of platinum-containing chemotherapy, or within range of 12 months of getting platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment.

Tecentriq/atezolizumab Cost/Price

This drug is administered by your healthcare practitioner (HCP), which usually means:
  • It may comes under special items category.
  • You cannot fill this prescription in a regular pharmacy. Your doctor, hospital, or clinic will provide this  medication because of possible complications or other issues.
  • This drug is likely to be covered under your medical benefit if you have insurance.

Tecentriq/atezolizumab Dosage

The usual dosage of tecentriq/atezolizumab is 1200 mg IV q3wk at rate 60min per infusion. This dosage frequency may be titrated in case of toxicity or increase the dosage in special instances to slow down the progression.